|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
 |
|
 |
||
|
||||
|
||||
|
|
|
|
|
|
||||||
|
|
|
||||||
|
Board of Directors
Paul Berns CEO, Allos Therapeutics
Paul Berns joined Allos as President and CEO in March 2006. From June 2002 to July 2005, Mr. Berns was President, Chief Executive Officer and a director of Bone Care International, Inc., a specialty pharmaceutical company that was acquired by Genzyme Corporation in 2005. From 2001 to 2002, Mr. Berns served as Vice President and General Manager of the Immunology, Oncology and Pain Therapeutics business unit of Abbott Laboratories. He served as Vice President, Marketing of BASF Pharmaceuticals-Knoll from 2000 to 2001. From 1990 to 2000, Mr. Berns held various positions, including senior management roles, at Bristol-Myers Squibb Company. Mr. Berns is a director of Xenoport, Inc.
Janis Naeve, PhD Director, Amgen Ventures
Dr. Naeve joined Amgen in 2005 as a Director in the Company's corporate venture capital fund. She directs the fund's investment in early-stage biotechnology companies focused on discovering and developing human therapeutics. From 2002 to 2005, Dr. Naeve was director of Corporate Development at X-Ceptor Therapeutics which was acquired by Exelixis. Prior to this she was director of Business Development at Aurora Biosciences where she led transactions for the ion channel technology business unit and managed the collaborations with Pfizer, Merck, Lilly and Bristol Myers-Squibb. Dr. Naeve holds a Ph.D. in Pathology from University of Southern California and completed a post-doctoral fellowship at the California Institute of Technology.
Tim Wollaeger Managing Director, Sanderling
Timothy Wollaeger has more than thirty years' experience in the medical products and biotechnology fields in both corporate management and venture capital. Mr. Wollaeger joined Sanderling Ventures as a Managing Director in 2002, and opened the firm's San Diego office. Mr. Wollaeger serves on the Board of Directors for several Sanderling portfolio companies, including Asteres, Triage Wireless, CalciMedica and REN. He is Chairman of the Board of Directors for Chimerix and is Chairman and CEO of Harkness Pharmaceuticals. Prior to joining Sanderling in 1994, Mr. Wollaeger founded the venture capital firm Kingsbury Capital Partners. At Kingsbury, seed and early stage investing was combined with active management and portfolio companies included Aurora Biosciences, Amylin Pharmaceuticals (NASDAQ: AMLN), Senomyx (NASDAQ: SNMX), and Althea Technologies. He was named E&Y San Diego's Entrepreneur of the Year in 1995 and Corporate Director of the Year in 2001. Prior to Kingsbury Capital Partners, Mr. Wollaeger helped found Columbia Hospital Corporation in 1990 and was a Senior Vice President and member of the Board of Directors until 1994. In 1986, Mr. Wollaeger became a founding General Partner of Biovest, a San Diego based venture capital firm. At Biovest, he helped found Pyxis, Biosite, Amlin Pharmaceuticals (NASDAQ: AMLN) and Vical (NASDAQ: VICL). All four of these companies became public. Pyxis was acquired by Cardinal Health in 1996 for $1 billion and Biosite was acquired by Inverness Technologies Inc. in 2007 for $1.7 billion. In 1983, Mr. Wollaeger joined Hybritech, Inc., San Diego's first biotechnology company, as Vice President and Chief Financial Officer until Hybritech was acquired by Eli Lilly & Co. (NYSE: LLY) in 1986.He began his Life Science career at Baxter International where he was Manager of Operations Analysis. His last position was Vice President and General Manager of the Company's operations in Mexico.
Mike Narachi, Chairman, Chief Executive Officer
Bryan Roberts Managing General Partner, Venrock Associates
Bryan joined Venrock as a Kauffman Fellow in 1997 and now serves as a Managing General Partner. Previously, he earned his PhD in Chemistry & Chemical Biology at Harvard University. Prior to his doctoral program, Bryan held corporate finance positions at Kidder, Peabody and Co. In 2006, Bryan was named a Henry Crown Fellow by the Aspen Institute.
Bill Wiesler, PhD Founder, Director of New Ventures in the Office of Cooperative Research, Yale University
Bill Wiesler serves within Yale's tech transfer group to found new ventures with Yale researchers, primarily in pharmaceuticals and medical devices. He previously held positions in management consulting at McKinsey & Company, in healthcare venture capital, and in drug discovery research. Dr. Wiesler is a summa cum laude graduate of Princeton University, and earned both an MBA and a PhD in Chemistry from Columbia University.
|
|
|
||||||
|
|
|
